NEW YORK (GenomeWeb News) – Sparked by preliminary fourth-quarter revenue results that surpassed analysts' consensus estimate and the launch of its new HiSeq 2000 sequencer, shares of Illumina jumped roughly 20 percent in the month of January.

The firm's stock was the top gainer for the month, followed by Cepheid (+18 percent) and Caliper Life Sciences (+17 percent).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

Harvard Medical School's George Church discusses editing human DNA, including germline DNA, in the New England Journal of Medicine.